Compare Tango Therapeutics Inc. (TNGX) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Yum! Brands, Inc. — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Yum! Brands, Inc. trades at $146.68 (market cap $40.13B). The key difference: Yum! Brands, Inc. is far larger — about 10.7× Tango Therapeutics Inc.'s market cap, and Yum! Brands, Inc. pays a 2.04% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Yum! Brands, Inc. for 133 Days on average.
| TNGX | YUM | |
|---|---|---|
Market Cap | $3.75B | $40.13B |
Volume | 9,619,106 | 2,329,777 |
Sector | Health | Consumer Cyclical |
52-Week High | $32.90 | $168.16 |
52-Week Low | $7.50 | $135.77 |
Typical Hold Time | 0 Days | 133 Days |
Enterprise Value | $2.77B | $51.73B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
YUM Brands trades at $146.69, showing minimal daily movement (-0.04%). The stock maintains a bullish technical outlook with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, YUM demonstrates solid revenue growth from $8.21B in 2025 to projected $8.7B in 2026, with net income margins improving to 25.4%. Recent strategic moves include the Pizza Hut divestiture and KFC's Open House concept launch, positioning the company for focused growth in its core brands.
YUM presents a compelling opportunity with analyst consensus target of $170.44 (16% upside), supported by consistent earnings beats and dividend growth. However, high debt levels ($11.25B long-term) and competitive pressures in the QSR space present notable risks. The company's streamlined portfolio and operational efficiency improvements provide catalysts for continued shareholder value creation amid industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
